Next Step for Onyx Pharma: 2011 Is Defining Year
Executive Summary
Onyx Pharmaceuticals Inc.’s growing pipeline, including one high-profile compound finishing successful Phase II clinical trials, appears to be finally moving the company beyond its considerable reliance on its flagship cancer drug Nexavar (sorafenib).
You may also be interested in...
Phase III Trial Of Bayer/Onyx Regorafenib Stopped Early For Efficacy
Interim analysis revealed the trial in advanced metastatic colorectal cancer had already met the overall survival endpoint.
Phase III Trial Of Bayer/Onyx Regorafenib Stopped Early For Efficacy
Interim analysis revealed the trial in advanced metastatic colorectal cancer had already met the overall survival endpoint.
Phase III Trial Of Bayer/Onyx Regorafenib Stopped Early For Efficacy
Interim analysis revealed the trial in advanced metastatic colorectal cancer had already met the overall survival endpoint.